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We read with interest the article by Yang et al [1] that
described the antiproteinuric effect of low-dose sulodexide in
IgA nephropathy patients who were already receiving renin–
angiotensin system (RAS) inhibitors. Reduction in proteinuria is
the key determining factor for renoprotective effects of any given
therapies for IgA nephropathy patients. RAS inhibition using
angiotensin-converting-enzyme inhibitors or angiotensin recep-
tor blockers is currently the most widely adopted renoprotective
therapy for IgA nephropathy. However, it is relatively common to
see IgA nephropathy patients with residual proteinuria despite
being treated with a maximal dose of RAS inhibitors. Therefore, it
is clinically relevant to investigate the beneﬁcial effect of sulo-
dexide on residual proteinuria. Sulodexide, a glycosaminoglycan
extract of porcine lung and liver, is composed of fast-moving
heparin sulfate (80%) and dermatan sulfate (20%). The heparan
sulfate content of sulodexide has been proposed to potentially
interfere with the abnormal biochemistry of the glomerular
capillary wall in patients with diabetic nephropathy and reduce
albuminuria. These hypoalbuminuric properties have been exten-
sively investigated in a multiple series of clinical studies on Type
2 diabetic patients with albuminuria with much controversy.
Recently, the Collaborative Study Group [2] reported that sulo-
dexide at 200 mg/day failed to decrease urine albumin excretion
in Type 2 diabetic nephropathy patients with microalbuminuria.
Nevertheless, few data exist on the use of sulodexide in non-
diabetic chronic kidney disease. Its potential efﬁcacy in treatment
of IgA nephropathy patients, especially those with residual
proteinuria, remains to be explored.
The results of the study are interesting. However, a big
limitation of the study, as underlined by the authors, is that it
is a retrospective study with only a small number of patients
enrolled. Therefore, the study results should be interpreted
with caution. Another limitation of the study is its lack of a
control group. Historical control group from the literature
may not be sufﬁcient. Whether add-on treatment of low-dose
sulodexide confers a signiﬁcant antiproteinuric effect in IgA
nephropathy patients with residual proteinuria currently
receiving RAS inhibitors is questionable.
The dose of sulodexide used in the study is considerably lower
than the dosage used in other trials [1,2]. A recent randomized
control trial in IgA nephropathy demonstrated an antiproteinuric
effect of sulodexide only in the 150mg arm [3]. There were some
nonresponders to sulodexide treatment, as shown in Fig. 1,
with an increase in urine protein creatinine ratio. As a group,132/$ - see front matter & 2013. The Korean Society of Nephrology. P
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dx.doi.org/10.1016/j.krcp.2012.12.005RAS inhibition demonstrates a signiﬁcant antiproteinuric
effect, but inter-individual variability to RAS inhibitors is well
known [4]. It would be interesting to see if these nonresponders
are a subgroup of patients who are also resistant to RAS
inhibition.
Finally, we are concerned about the some other clinical
factors that might inﬂuence the antiproteinuric effects of RAS
inhibition and sulodexide. Medication history is limited to
only the number and duration of RAS inhibitors used. Dietary
sodium and protein intake can inﬂuence urine protein excre-
tion in patients with renal disease. A low-sodium diet and use
of diuretics potentiate the antiproteinuric effects of RAS
inhibitors [5]. As in any other clinical studies, more attention
should be directed to dietary sodium intake.
Considering that no safety issues had occurred during the
study, a larger randomized controlled trial with higher dose
would be most helpful in demonstrating the future utility of
sulodexide in proteinuric renal diseases.
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2008In Reply:
Dear Sirs,
We appreciate your interest in our recent paper. As you
mentioned, our study has several ﬂaws. We conducted a case
series study dealing with uncontrolled paired comparisons.
With a retrospective analysis, it was hard for us to get
matched controls that had an equivalent additional observa-
tion period to the add-on therapy. We tried to ﬁnd historical
controls, but trials that were possible matches were nonho-
mogeneous. Besides, the small sample size could not sufﬁ-
ciently yield an conclusive effect, and even showed negative
outcomes in some patients.
Another concern was raised regarding the sulodexide dose
(50 mg daily) used in our study. We anecdotally used this
dose and there was no dose escalation during the treatment
period. Although Blouza et al [1] reported the efﬁcacy of low-
dose sulodexide (50 mg daily) in the management of diabetic
nephropathy, we did not extrapolate their result to our study.
There is a different aspect we observed as follows.
Bang et al recently published the ﬁrst randomized con-
trolled trial of sulodexide therapy in IgA nephropathy [2]. The
baseline proteinuria of the patients in their trial was not
signiﬁcantly high, suggesting that the most of the patients
would be already be in a range of partial remission [urinary
protein to creatinine ratio (UPCR) o1.0 g/g] at baseline,
which means they dealt with a different study population
from ours. In our study, the nearly 1-year use of low-dose
sulodexide in the patients having UPCR 41.0 g/g correlated
to high response rate.
Reich et al studied a large cohort and demonstrated a
relationship between time-average proteinuria and renalsurvival in IgA nephropathy [3]. They showed that the
outcome of patients with a partial remission of proteinuria
with a UCPR of 0.3–1.0 g/g was not inferior to that of patients
with complete remission. Partial remission could be an alter-
native target in the management of IgA nephropathy, whereas
complete remission is the ultimate goal.
As you pointed out, our study is lacking in some data
essential to guarantee the quality of the results. Further investiga-
tions for the use of sulodexide in IgA nephropathy are needed to
clarify its effectiveness.
Conﬂicts of interest
All contributing authors declare no conﬂict of interest.
Byeong Yun Yang, Sang Heon Songn
Division of Nephrology,
Department of Internal Medicine,
Pusan National University Hospital,
Pusan National University School of Medicine,
179 Gudeok-ro, Seo-gu, Busan, 602-739, Korea
nE-mail address: shsong@pusan.ac.kr (S–H Song).References
[1] Blouza S, Dakhli S, Abid H, Aissaoui M, Ardhaoui I, Ben
Abdallah N, Ben Brahim S, Ben Ghorbel I, Ben Salem N, Beji S,
Chamakhi S, Derbel A, Derouiche F, Djait F, Doghri T, Fourti Y,
Gharbi F, Jellouli K, Jellazi N, Kamoun K, Khedher A, Letaief A,
Limam R, Mekaouer A, Miledi R, Nagati K, Naouar M, Sellem S,
Tarzi H, Turki S, Zidi B, Achour A; DAVET (Diabetic Albumi-
nuria Vessel Tunisia Study Investigators): Efﬁcacy of low-dose
oral sulodexide in the management of diabetic nephropathy.
J Nephrol. 23:415–424, 2010
[2] Bang K, Chin HJ, Chae DW, Joo KW, Kim YS, Kim S, Ju KD,
Kim H, Ahn C, Oh KH: Anti-proteinuric effect of sulodexide
in immunoglobulin a nephropathy. Yonsei Med J 52:588–594,
2011
[3] Reich HN, Troyanov S, Scholey JW, Cattran DC; Toronto
Glomerulonephritis Registry: Remission of proteinuria improves
prognosis in IgA nephropathy. J Am Soc Nephrol. 18:3177–3183,
2007
Available online 31 December 2012
